Baxalta — Merger or Acquisition (August 2015)
22 slides from Baxalta's merger presentation, Aug 4, 2015
Slide 1: 20x20 Creating the Global Leader in Rare Diseases
20x20 Creating the Global Leader in Rare Diseases
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Statements included herein that are not historical facts, including without limitation statements concerning our proposed business combination with Baxalta Incorporated (“Baxalta”), and the timing and benefits thereof, including our 20x20 ambition that targets $20 billion
Slide 3: Third Party-Sourced Information and Additional Information
Third Party-Sourced Information All information in this press release regarding Baxalta, including its businesses, operations and financial results, was obtained from public sources. While Shire has no knowledge that any such information is inaccurate or incomplete, Shire has not verified any of tha
Slide 4: Basis of Shire forecasts and Long Range Plan
The Shire forecasts included in this presentation are derived from Shire’s Long Range Plan (the "LRP") and Shire papers subsequently produced as part of the business planning process. Shire produces a long range plan annually. The LRP was updated in March 2015, as part of Shire’s annual planning cyc
Slide 5: Background and Shire proposal to Baxalta
Background • On 1 July 2015, Baxalta, formerly the BioScience division of Baxter, was spun off and became an independent, publicly-traded company Subsequent events • Recognizing an opportunity to generate significant shareholder value and accelerate the growth plans of both Shire and Baxalta by crea
Slide 6: The global leader in rare diseases
The global leader in rare diseases • • • ~$20B in product sales by 2020 (“20x20”) Multiple $1B+ high-value rare diseases franchises with substantial barriers to entry Complementary expertise in rare diseases R&D, commercial, and manufacturing, supported by global scale and infrastructure Compelling
Slide 7: Shire strategy and superior shareholder returns
We have generated improved outcomes for patients and superior shareholder returns by executing a strategy focused on: 60.0 +204.0% Accelerating long-term growth through commercial excellence and M&A; Enhancing domain expertise and building our pipeline in core and adjacent TAs; Improving profitabili
Slide 8: Shire: sustained financial performance and rare diseases focus
Sustained superior financial performance and strong cash generation Focus on core Therapeutic Areas (TAs) 40% of product sales come from rare diseases We bring a rare diseases mindset to all our businesses +6% points improvement in Non GAAP EBITDA margin in 2014(1,2) 23% product sales growth in 2014
Slide 9: Baxalta: three growing businesses focused on rare diseases
Three growing and sustainable businesses focused on rare diseases Accelerating sales with 6% - 8% CAGR driven by ~20 new product launches by 2020 • High, competitive margins and strong free cash flow growth • New product revenue growing from ~$0.2B in 2015 to more than ~$2.5B in 2020 • Building a 3r
Slide 10: Complementary strengths of Shire and Baxalta
“Leading global biotech delivering innovative medicines to patients with rare diseases and specialty “Global biopharmaceutical company focused on delivering innovation that Vision provides patients with better treatment options for challenging chronic and rare diseases”(2) conditions”(1) Complementa
Slide 11: 20 x 20: project ~$20B in product sales by 2020
Shire >10% CAGR ~$10+B(1) Together ~$20B(3) 2015E 2020E Baxalta 7% CAGR 2015E 2020E ~$8+B(2) 2015E 2020E 11 (1) Estimated results based on Shire management assumptions. (2) Estimated future results based on Baxalta investor presentations and Form 10 disclosures, using Baxalta accounting policies. (3
Slide 12: Highly complementary rare diseases capabilities
12 Source: Baxalta investor presentations and Form 10 disclosures. Shire Baxalta Shire and Baxalta have highly complementary rare diseases capabilities
Slide 13: Leading franchises and brands
Leading franchises and brands Projected 2020 product sales breakdown(3) Lifitegrast1 ~$20B / Other Rare diseases 2020 (1) If approved by regulatory authorities. (2) Baxalta investor presentations 19 May 2015. (3) Estimated combined results based on Shire management assumptions and Baxalta investor p
Slide 14: Combined rare diseases platform
Combined rare diseases platform SM101 Calaspargase pegol Pacritinib SHP631 SHP611 SHP635 SHP622 #1in rare Rigosertib SHP609 nal-IRI diseases BAX 069 SHP610 BAX 555 ~$13B in 2020 rare diseases revenue(1); >50 products / programs(2) SHP627 SHP625 BAX 826 SHP620 SHP621 BAX 930 BAX 335 BAX 817 BAX 855 S
Slide 15: Combined pipeline by development phase
Preclinical 26 Research programs Phase 1 SHP611 MLD (Ph 1/2) Phase 2 Phase 3(3) Firazyr ACE inhibitor-induced AE Firazyr (Japan) HAE SHP616 (Cinryze) (Japan) HAE prophylaxis Registration NATPARA (EU) Hypoparathyroidism SHP607 Prevention of ROP SHP625 Alagille syndrome TH / GCH1 Gene pod Parkinson’s
Slide 16: Significant synergy opportunity and scale efficiencies
• • • • Lean global support (G&A) functions Additional commercial and R&D efficiencies Streamlined systems and processes “Best of both” approach • • • • ~15 combined internal manufacturing sites Strong capabilities in managing CMO relationships Increased scale in global supply chain Efficient centra
Slide 17: Compelling financial profile
Compelling financial profile: Double-digit top-line compound annual growth(1) Significant operating synergies Attractive combined tax profile – ~16-17% projected combined Non GAAP effective tax rate by 2017 Accretive to Non GAAP earnings(2) – breakeven in year one, with accretion thereafter • • • •
Slide 18: Benefits accrue to shareholders of both companies
flexibility for future M&A 18 Shire shareholders expected to benefit from… •Accelerated strategic plan: 10 x 20 20 x 20 •Enhanced Non GAAP EPS and cash flows •Increased scale with preserved •Diversification Baxalta shareholders expected to benefit from… •Immediate significant premium •Acceleration a
Slide 19: Opportunity for key stakeholders beyond investors
19 (1) Largest by revenue. For our people – rewarding opportunity for growth • Develop and deliver innovative therapies for patients in need • Entrepreneurial biotech culture with career growth opportunities • Individuals valued and rewarded for their contributions For our patients and physicians –
Slide 20: Now is the time to act
• The global leader in rare diseases (“20 x 20”) • Compelling financial profile creation and value • Strong future outlook 20 Now is the time to act – we encourage Baxalta to engage without further delay on this value-creating combination Baxalta’s shareholders deserve a chance to consider this stra
Slide 21: Appendix
Appendix 2 | |
Slide 22: Non GAAP financial measures
This presentation contains financial measures not prepared in accordance with US GAAP. These Non GAAP measures exclude the effect of certain cash and non-cash items, that Shire's management believes are not related to the core performance of Shire’s business. These Non GAAP financial measures are us